MTOR and interstitial lung disease: By analyzing a large and diverse patient population, we identified that multiple novel antineoplastic agents, particularly monoclonal antibodies, antibody-drug conjugates, immune checkpoint inhibitors, and mTOR inhibitors, showed signals of disproportionate reporting associated with ILD.